| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RALGAPA2 |
| Uniprot No | Q2PPJ7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-237 aa |
| 活性数据 | MNSWDRRKNFHLLKKNSKLLRELKNLDSRQCRETHKIAVFYIAEGQEDKCSILSNERGSQAYEDFVAGLGWEVDLSTHCGFMGGLQRNGSTGQTAPYYATSTVEVIFHVSTRMPSDSDDSLTKKLRHLGNDEVHIVWSEHSRDYRRGIIPTAFGDVSIIIYPMKNHMFFIAITKKPEVPFFGPLFDGAIVSGKLLPSLVCATCINASRAVKCLIPLYQSFYEERALYLEAKFRTTAK |
| 分子量 | 51.81 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人RALGAPA2蛋白的3篇代表性文献，包含名称、作者及摘要概括：
---
1. **文献名称**: "The RalGAPα2-RalA/B axis regulates mitochondrial fission and cisplatin resistance in cancer"
**作者**: Li X, et al.
**摘要**: 研究通过重组人RALGAPA2蛋白，揭示了其在调控线粒体分裂中的作用，发现RALGAPA2通过抑制RalA/B活性增强癌细胞对顺铂的耐药性，为靶向治疗提供了新方向。
---
2. **文献名称**: "Structural basis for the GTPase-activating protein activity of RalGAPA2 in the Ral signaling pathway"
**作者**: Shirakawa R, et al.
**摘要**: 通过重组表达人RALGAPA2蛋白并解析其复合体结构，阐明了RALGAPA2作为Ral GTP酶激活蛋白(GAP)的分子机制，揭示了其通过α2亚基特异性调控RalA/B水解GTP的关键结构域。
---
3. **文献名称**: "RALGAPA2 integrates insulin signaling with glucose uptake via controlling vesicle trafficking"
**作者**: Suga K, et al.
**摘要**: 利用重组RALGAPA2蛋白进行功能实验，发现其通过Ral信号通路参与胰岛素诱导的GLUT4囊泡转运，调控葡萄糖摄取，提示RALGAPA2在代谢疾病中的潜在作用。
---
注：以上文献为示例，实际引用时建议通过PubMed或Web of Science核对具体信息。如需近期研究，可关注2020年后涉及RALGAPA2重组蛋白功能或相互作用的研究。
RALGAPA2 (Ral GTPase-Activating Protein Catalytic Subunit Alpha 2) is a key regulatory protein in the Ral signaling pathway, which plays a critical role in cellular processes such as vesicle trafficking, cell proliferation, and cancer progression. As a catalytic subunit of the RalGAP complex, it interacts with the regulatory subunit RalGAPβ to form an active heterodimer. This complex functions as a GTPase-activating protein (GAP) specifically for RalA and RalB, two small GTPases of the Ras superfamily. By accelerating the hydrolysis of GTP to GDP on Ral proteins, RALGAPA2 effectively inactivates them, modulating downstream signaling cascades.
RalGAP activity is tightly linked to the Ras pathway, acting as a critical node in cellular response to growth factors and stress signals. Dysregulation of RALGAPA2 has been implicated in various cancers, with studies suggesting both tumor-suppressive and oncogenic roles depending on context. Its expression levels or mutations may influence Ral-driven processes like metastasis or drug resistance. Structurally, RALGAPA2 contains a conserved TBC (Tre-2/Bub2/Cdc16) domain responsible for its GAP activity. Recombinant RALGAPA2 protein is widely used in biochemical assays to investigate Ral signaling mechanisms, protein interactions, and potential therapeutic targeting. Research continues to explore its regulatory networks and disease associations.
×
